Literature DB >> 14632630

Duchenne's muscular dystrophy: animal models used to investigate pathogenesis and develop therapeutic strategies.

C A Collins1, J E Morgan.   

Abstract

Duchenne's muscular dystrophy (DMD) is a lethal childhood disease caused by mutations of the dystrophin gene, the protein product of which, dystrophin, has a vital role in maintaining muscle structure and function. Homologues of DMD have been identified in several animals including dogs, cats, mice, fish and invertebrates. The most notable of these are the extensively studied mdx mouse, a genetic and biochemical model of the human disease, and the muscular dystrophic Golden Retriever dog, which is the nearest pathological counterpart of DMD. These models have been used to explore potential therapeutic approaches along a number of avenues including gene replacement and cell transplantation strategies. High-throughput screening of pharmacological and genetic therapies could potentially be carried out in recently available smaller models such as zebrafish and Caenorhabditis elegans. It is possible that a successful treatment will eventually be identified through the integration of studies in multiple species differentially suited to addressing particular questions.

Entities:  

Mesh:

Year:  2003        PMID: 14632630      PMCID: PMC2517561          DOI: 10.1046/j.1365-2613.2003.00354.x

Source DB:  PubMed          Journal:  Int J Exp Pathol        ISSN: 0959-9673            Impact factor:   1.925


  64 in total

1.  Dystrobrevin- and dystrophin-like mutants display similar phenotypes in the nematode Caenorhabditis elegans.

Authors:  K Gieseler; C Bessou; L Ségalat
Journal:  Neurogenetics       Date:  1999-04       Impact factor: 2.660

2.  In vivo targeted repair of a point mutation in the canine dystrophin gene by a chimeric RNA/DNA oligonucleotide.

Authors:  R J Bartlett; S Stockinger; M M Denis; W T Bartlett; L Inverardi; T T Le; N thi Man; G E Morris; D J Bogan; J Metcalf-Bogan; J N Kornegay
Journal:  Nat Biotechnol       Date:  2000-06       Impact factor: 54.908

3.  Long-term persistence and migration of myogenic cells injected into pre-irradiated muscles of mdx mice.

Authors:  J E Morgan; C N Pagel; T Sherratt; T A Partridge
Journal:  J Neurol Sci       Date:  1993-04       Impact factor: 3.181

4.  Mutations in the Caenorhabditis elegans dystrophin-like gene dys-1 lead to hyperactivity and suggest a link with cholinergic transmission.

Authors:  C Bessou; J B Giugia; C J Franks; L Holden-Dye; L Ségalat
Journal:  Neurogenetics       Date:  1998-12       Impact factor: 2.660

5.  Myoblast transplantation in whole muscle of nonhuman primates.

Authors:  D Skuk; M Goulet; B Roy; J P Tremblay
Journal:  J Neuropathol Exp Neurol       Date:  2000-03       Impact factor: 3.685

6.  T-cell-dependent fibrosis in the mdx dystrophic mouse.

Authors:  J Morrison; Q L Lu; C Pastoret; T Partridge; G Bou-Gharios
Journal:  Lab Invest       Date:  2000-06       Impact factor: 5.662

7.  Cardiomyopathy in dystrophin-deficient hypertrophic feline muscular dystrophy.

Authors:  L Gaschen; J Lang; S Lin; M Adé-Damilano; A Busato; C W Lombard; F P Gaschen
Journal:  J Vet Intern Med       Date:  1999 Jul-Aug       Impact factor: 3.333

8.  In vitro interactions of Caenorhabditis elegans dystrophin with dystrobrevin and syntrophin.

Authors:  K Gieseler; M Abdel-Dayem; L Ségalat
Journal:  FEBS Lett       Date:  1999-11-12       Impact factor: 4.124

Review 9.  Progress in myoblast transplantation: a potential treatment of dystrophies.

Authors:  D Skuk; J P Tremblay
Journal:  Microsc Res Tech       Date:  2000 Feb 1-15       Impact factor: 2.769

10.  Prevention of the dystrophic phenotype in dystrophin/utrophin-deficient muscle following adenovirus-mediated transfer of a utrophin minigene.

Authors:  P M Wakefield; J M Tinsley; M J Wood; R Gilbert; G Karpati; K E Davies
Journal:  Gene Ther       Date:  2000-02       Impact factor: 5.250

View more
  56 in total

Review 1.  Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment.

Authors:  Kristen J Nowak; Kay E Davies
Journal:  EMBO Rep       Date:  2004-09       Impact factor: 8.807

2.  Eccentric stimulation reveals an involvement of FGF6 in muscle resistance to mechanical stress.

Authors:  Iman Laziz; Arnaud Ferry; Anne-Sophie Armand; Claude Louis Gallien; Bruno Della Gaspera; F Charbonnier; C Chanoine
Journal:  Eur J Appl Physiol       Date:  2010-12-25       Impact factor: 3.078

Review 3.  What has the mdx mouse model of Duchenne muscular dystrophy contributed to our understanding of this disease?

Authors:  Jennifer Manning; Dervla O'Malley
Journal:  J Muscle Res Cell Motil       Date:  2015-02-11       Impact factor: 2.698

Review 4.  Challenges for gene therapy for muscular dystrophy.

Authors:  Jerry R Mendell; K Reed Clark
Journal:  Curr Neurol Neurosci Rep       Date:  2006-01       Impact factor: 5.081

5.  Effects of non-euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice.

Authors:  Fabio Arturo Iannotti; Ester Pagano; Aniello Schiano Moriello; Filomena Grazia Alvino; Nicolina Cristina Sorrentino; Luca D'Orsi; Elisabetta Gazzerro; Raffaele Capasso; Elvira De Leonibus; Luciano De Petrocellis; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2018-09-09       Impact factor: 8.739

Review 6.  Gene therapy in large animal models of muscular dystrophy.

Authors:  Zejing Wang; Jeffrey S Chamberlain; Stephen J Tapscott; Rainer Storb
Journal:  ILAR J       Date:  2009

Review 7.  Animal models for genetic neuromuscular diseases.

Authors:  Mariz Vainzof; Danielle Ayub-Guerrieri; Paula C G Onofre; Poliana C M Martins; Vanessa F Lopes; Dinorah Zilberztajn; Lucas S Maia; Karen Sell; Lydia U Yamamoto
Journal:  J Mol Neurosci       Date:  2008-01-18       Impact factor: 3.444

8.  Inhibition of CaMKII phosphorylation of RyR2 prevents inducible ventricular arrhythmias in mice with Duchenne muscular dystrophy.

Authors:  Sameer Ather; Wei Wang; Qiongling Wang; Na Li; Mark E Anderson; Xander H T Wehrens
Journal:  Heart Rhythm       Date:  2012-12-12       Impact factor: 6.343

9.  Long-term treatment with naproxcinod significantly improves skeletal and cardiac disease phenotype in the mdx mouse model of dystrophy.

Authors:  Kitipong Uaesoontrachoon; James L Quinn; Kathleen S Tatem; Jack H Van Der Meulen; Qing Yu; Aditi Phadke; Brittany K Miller; Heather Gordish-Dressman; Ennio Ongini; Daniela Miglietta; Kanneboyina Nagaraju
Journal:  Hum Mol Genet       Date:  2014-01-23       Impact factor: 6.150

10.  Genetic elevation of sphingosine 1-phosphate suppresses dystrophic muscle phenotypes in Drosophila.

Authors:  Mario Pantoja; Karin A Fischer; Nicholas Ieronimakis; Morayma Reyes; Hannele Ruohola-Baker
Journal:  Development       Date:  2012-11-15       Impact factor: 6.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.